NGM Biopharmaceuticals 被 The Column Group 以每股 1.55 美元现金收购，相当于 80% 的溢价，交易金额为 1.35 亿美元。 NGM Biopharmaceuticals is being acquired by The Column Group for $1.55/share in cash, representing an 80% premium, in a $135M deal.

NGM Biopharmaceuticals 的最大股东 The Column Group 同意以每股 1.55 美元现金收购该公司后，该公司股价今日走低。 NGM Biopharmaceuticals stock is trading lower today after The Column Group, its largest stockholder, agreed to acquire the company for $1.55/share in cash. 这笔 1.35 亿美元的交易比之前的收盘价溢价 80%。 The $135 million deal represents an 80% premium over the previous closing price. 风险投资公司 Column Group 持有 NGM Bio 约 26% 的流通股。 The Column Group, a venture capital firm, holds approximately 26% of NGM Bio's outstanding shares. 该交易预计将于 2024 年第二季度完成，之后 NGM Bio 将成为一家私人控股公司。 The transaction is expected to be completed in Q2 2024, after which NGM Bio will become a privately held company.